PATHOGENETIC THERAPY OF DIABETIC POLYNEUROPATHY
V.V. Oganov, I.A. Strokov
For quotation:
Oganov V.V., Strokov I.A. Pathogenetic therapy of diabetic polyneuropathy, Pharmacology &
Pharmacotherapy. 2021. No. 2. pp. 18–24.
DOI 10.46393/2713-2129_2021_2_18_24
Annotation:
Diabetic polyneuropathy (DPN) is the most common complication of diabetes mellitus (DM), observed in almost 50% of patients with type 1 and 2 diabetes. Only good compensation of diabetes reduces the risk of development and progression of DPN in type 1 diabetes, but does not affect the formation and progression of DPN in type 2 diabetes. In this regard, it is important to carry out pathogenetic
treatment of DPN with drugs acting on the mechanisms of cellular pathology in diabetes. The main treatment for DPN is the natural antioxidant alpha lipoic acid (ALA). Another drug, benfotiamine, a fat-soluble thiamine, reduces metabolic disorders. A combination of these drugs is possible in the treatment of DPN. The review examines the main randomized controlled trials of the effectiveness of ALA and benfotiamine in DPN.
Journal "Pharmacology & Pharmacotherapy" No. 2_2021
https://drive.google.com/file/d/1gkPo0CAeOvbxxI_HhJd7cj0c3NUArzKQ/view
V.V. Oganov, I.A. Strokov
For quotation:
Oganov V.V., Strokov I.A. Pathogenetic therapy of diabetic polyneuropathy, Pharmacology &
Pharmacotherapy. 2021. No. 2. pp. 18–24.
DOI 10.46393/2713-2129_2021_2_18_24
Annotation:
Diabetic polyneuropathy (DPN) is the most common complication of diabetes mellitus (DM), observed in almost 50% of patients with type 1 and 2 diabetes. Only good compensation of diabetes reduces the risk of development and progression of DPN in type 1 diabetes, but does not affect the formation and progression of DPN in type 2 diabetes. In this regard, it is important to carry out pathogenetic
treatment of DPN with drugs acting on the mechanisms of cellular pathology in diabetes. The main treatment for DPN is the natural antioxidant alpha lipoic acid (ALA). Another drug, benfotiamine, a fat-soluble thiamine, reduces metabolic disorders. A combination of these drugs is possible in the treatment of DPN. The review examines the main randomized controlled trials of the effectiveness of ALA and benfotiamine in DPN.
Journal "Pharmacology & Pharmacotherapy" No. 2_2021
https://drive.google.com/file/d/1gkPo0CAeOvbxxI_HhJd7cj0c3NUArzKQ/view
